Spatial and transcriptomic analyses reveal the adverse prognostic impact of regulatory T cells in follicular lymphoma treated with rituximab–lenalidomide
Year: 2026
Type: article
Abstract: Summary The prognostic impact of the tumour microenvironment in follicular lymphoma (FL) remains controversial. To adress this, we analysed FL samples from patients enrolled in the rituximab lenalidomide versus any chemotherapy (RELEVANCE) trial using RNA‐sequencing (RNA‐seq) and multiplex immunofluorescence (mIF). RNA‐seq analysis ( n = 354) showed that regulatory T‐cell (Treg) signatures were associated with shorter PFS in the whole cohort (HR = 1.56, 95% CI: 1.01–2.41, p = 0.044), particularly in patients treated with rituximab–lenalidomide (LEN) (R2, HR= 1.84, 95% CI: 1–3.37, p = 0.046) but not with rituximab‐chemotherapy (R‐chemo, HR = 1.33, 95% CI: 0.71–2.48, p = 0.365). mIF analysis on tissue microarrays (TMA) ( n = 394) showed that high infiltration of CD3 + /CD4 + /FOXP3 + Tregs was associated with shorter PFS in the overall cohort (HR = 1.951, CI: 1.259–3.024, p = 0.0023 log‐rank test), particularly in the R2 arm (HR = 2.3, CI: 1.2–4.5, p = 0.0097 log‐rank test) and remained significant after FL‐International Prognostic Index (FLIPI) adjustment (HR = 1.843; 95% CI: 1.1–2.8, p = 0.006). Whole‐slide mIF (WSI) performed in 64 selected cases confirmed the adverse prognostic impact of Tregs in R2‐treated patients and further showed that extra‐follicular Treg localization was specifically associated with shorter PFS (HR = 2.87, 95% CI: 1.13–7.28, p = 0.020). These data suggest that high Treg infiltration by mIF is associated with inferior outcome in lenalidomide‐treated FL patients and may have potential value for risk stratification.
Source: British Journal of Haematology
DOI: 10.1111/bjh.70934
Authors: Camille Laurent(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing), Marie Tosolini(Conceptualization, Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing – review & editing), Arnaud Guille(Conceptualization, Formal analysis, Methodology, Validation, Visualization), Bruno Tesson(Conceptualization, Methodology, Resources, Supervision), Nathalie Van‐Acker(Formal analysis, Methodology, Supervision, Visualization), François‐Xavier Frenois(Formal analysis, Methodology, Visualization), Andrea Belin‐Artola(Formal analysis, Methodology, Visualization), Bastien Lesne(Formal analysis, Methodology), Pierre Brousset(Funding acquisition, Resources), Franck Morschhauser(Funding acquisition, Project administration, Resources, Writing – review & editing), Luc Xerri(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing)
Institutions: Inserm, Centre Hospitalier Universitaire de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, The Lymphoma Academic Research Organisation, Hôpital Claude Huriez
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funders: Bristol-Myers Squibb, Aix-Marseille Université, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Ligue Contre le Cancer, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Université de Recherche Paris Sciences et Lettres, Etablissement Français du Sang, Université de Versailles Saint-Quentin-en-Yvelines
Award: G1002006804
OpenAlex ID: W7234564325
